BX211
AXP000218.1 · Phage therapy
- Platform
- personalised phage therapy (PhageBank)
- Originator
- Adaptive Phage Therapeutics
- Sponsor
- BiomX
Names
| Name | Type | Source |
|---|---|---|
| BX211 | preferred name, code | curator, press |
Virus
- Role
- Phage
- Family
- Caudoviricetes
- Virus
- Staphylococcus aureus bacteriophage (patient-matched from a phage bank)
- Replication
- replicating
- Source
- evidence
Approvals
No regulatory approval recorded.
Clinical trials (0)
No trial in the latest ClinicalTrials.gov snapshot names this program.
Recent changes
No changes recorded in its trials yet.
Notes
Personalised anti-Staphylococcus aureus phage treatment for diabetic foot osteomyelitis, matched to the patient's isolate from the PhageBank collection. Developed by Adaptive Phage Therapeutics, which BiomX acquired in March 2024; the phase 2 DANCE trial NCT05177107 (APT.DFI.001) is the trial BiomX reported as positive BX211 topline data in March 2025, so BX211 and the APT DFO product are one program, not two. Route not taken from a primary source yet, so left empty. PhageBank itself is a platform (SPEC section 1), not a program.
How to cite
BX211 (AXP000218.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000218.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.